Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01635283 · ClinicalTrials.gov registry record · Phase 2
Vaccine for Patients With Newly Diagnosed or Recurrent Low-Grade Glioma
A Phase 2 study, sponsored by Jonsson Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT01635283 is a Phase 2 study that has completed, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 5 participants.
The verdict
NCT01635283, a Phase 2 study, has completed, sponsored by Jonsson Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
The primary purpose of this phase II clinical trial is to determine the safety and effect on survival of patients autologous dendritic cells pulsed with autologous tumor lysate as a treatment for low-grade glioma patients. Other goals of this study are to determine if the vaccine can cause an immune response against patients' cancer cells and slow the growth of their brain tumors
Interventions
- OTHER laboratory biomarker analysis
- BIOLOGICAL tumor lysate-pulsed autologous dendritic cell vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2012-01-10 |
| Est. Completion | 2016-05-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01635283
The ClinicalTrials.gov registry entry for NCT01635283 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jonsson Comprehensive Cancer Center, which has 321 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which laboratory biomarker analysis is the first listed.
NCT01635283 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01635283 about?
NCT01635283 is a clinical study titled "Vaccine for Patients With Newly Diagnosed or Recurrent Low-Grade Glioma". The primary purpose of this phase II clinical trial is to determine the safety and effect on survival of patients autologous dendritic cells pulsed with autologous tumor lysate as a treatment for low-grade glioma patients. Other goals of this study are to determine if the vaccine can cause an immune...
What is the current status of trial NCT01635283?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2012-01-10. Estimated completion is 2016-05-13.
What interventions are being tested in trial NCT01635283?
The interventions under investigation include: laboratory biomarker analysis (OTHER), tumor lysate-pulsed autologous dendritic cell vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT01635283?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.